Table 2.
Patient-dependent parameters
| Total [n] | Unsuspicious [n; (%)] | Suspicious [n; (%)] | SufficientX [n; (%)] | Insufficient [n; (%)] | p-valueY | Odds ratioY | 95% CIY | |
|---|---|---|---|---|---|---|---|---|
| Total | 90 | 59 (65.6%) | 20 (22.2%) | 79 (87.8%) | 11 (12.2%) | |||
| Sex | ||||||||
| Male | 48 | 31 (64.6) | 11 (22.9) | 42 (87.5) | 6 (12.5) | 1 (Ref) | ||
| Female | 42 | 28 (66.7) | 9 (21.4) | 37 (88.1) | 5 (11.9) | 0.931 | 1.06 | 0.3–3.75 |
| Indication for surgery | ||||||||
| Carcinoma | 54 | 33 (61.1) | 15 (27.8) | 48 (88.9) | 6 (11.1) | 1 (Ref) | ||
| Benign disease | 36 | 26 (72.2) | 5 (13.9) | 31 (86.1) | 5 (13.9) | 0.693 | 0.78 | 0.22–2.76 |
| IBD | 8 | 6 (75) | 2 (25) | 8 (100) | 0 (0) | 0.44 | 0.02–8.5 | |
| Inflammation | 15 | 13 (86.7) | 1 (6.7) | 14 (93.3) | 1 (6.7) | 0.57 | 0.06–5.15 | |
| Other | 13 | 7 (53.8) | 2 (15.4) | 9 (69.2) | 4 (30.8) | 3.56 | 0.83–15.18 | |
| UICC stage | ||||||||
| UICC 0 | 1 | 1 (100) | 0 (0) | 1 (100) | 0 (0) | 2.56 | 0.07–95.89 | |
| UICC I | 12 | 5 (41.7) | 6 (50) | 11 (91.7) | 1 (8.3) | 1 (Ref) | ||
| UICC II | 6 | 5 (83.3) | 1 (16.7) | 6 (100) | 0 (0) | 0.59 | 0.02–16.68 | |
| UICC III | 19 | 11 (57.9) | 5 (26.3) | 16 (84.2) | 3 (15.8) | 2.06 | 0.19–22.51 | |
| UICC IV | 16 | 11 (68.8) | 3 (18.8) | 14 (87.5) | 2 (12.5) | 0.927 | 1.57 | 0.13–19.67 |
| Immunosuppression | ||||||||
| No | 81 | 55 (67.9) | 18 (22.2) | 73 (91.1) | 8 (9.9) | 1 (Ref) | ||
| Yes | 9 | 4 (44.4) | 2 (22.2) | 6 (66.6) | 3 (33.3) | 0.042 | 4.56 | 0.95–21.85 |
| Alcohol abuse | ||||||||
| No | 85 | 55 (64.7) | 19 (22.4) | 74 (87.1) | 11 (12.9) | 1 (Ref) | ||
| Yes | 5 | 4 (80) | 1 (20) | 5 (100) | 0 (0) | 0.391 | 0.59 | 0.03–11.38 |
| Neoadjuvant therapy | ||||||||
| None | 68 | 48 (70.6) | 14 (20.6) | 62 (91.2) | 6 (8.8) | 1 (Ref) | ||
| Yes | 22 | 11 (50) | 6 (27.3) | 17 (77.3) | 5 (22.7) | 0.2 | 3.04 | 0.83–11.18 |
| RTx | 2 | 0 (0) | 1 (50) | 1 (50) | 1 (50) | 10.3 | 0.57–187 | |
| CTx | 9 | 6 (66.7) | 1 (11.1) | 7 (77.8) | 2 (22.2) | 2.95 | 0.5–17.5 | |
| CRTx | 11 | 5 (45.5) | 4 (36.4) | 9 (81.8) | 2 (18.2) | 2.3 | 0.4–13.2 | |
| Diabetes mellitus type 2 | ||||||||
| No | 75 | 50 (66.7) | 16 (21.3) | 66 (88) | 9 (12) | 1 (Ref) | ||
| Yes | 15 | 9 (60) | 4 (26.7) | 13 (86.7) | 2 (13.3) | 0.886 | 1.13 | 0.22–5.84 |
| Cardiovascular comorbidities | ||||||||
| No | 42 | 27 (64.3) | 7 (16.7) | 34 (81) | 8 (19) | 1 (Ref) | ||
| Yes | 48 | 32 (66.7) | 13 (27.1) | 45 (83.9) | 3 (6.3) | 0.064 | 3.5 | 0.87–14.31 |
| Pulmonary comorbidities | ||||||||
| No | 79 | 52 (65.8) | 18 (22.8) | 70 (88.6) | 9 (11.4) | 1 (Ref) | ||
| Yes | 11 | 7 (63.6) | 2 (18.2) | 9 (81.8) | 2 (18.2) | 0.52 | 1.73 | 0.32–9.3 |
| Hepatic comorbidities | ||||||||
| No | 88 | 57 (64.8) | 20 (22.7) | 77 (87.5) | 11 (12.5) | 1 (Ref) | ||
| Yes | 2 | 2 (100) | 0 (0) | 2 (100) | 0 (0) | 0.584 | 1.35 | 0.06–29.89 |
| Renal comorbidities | ||||||||
| No | 84 | 55 (65.5) | 20 (23.8) | 75 (89.3) | 9 (10.7) | 1 (Ref) | ||
| Yes | 6 | 4 (66.7) | 0 (0) | 4 (66.7) | 2 (33.3) | 0.102 | 4.16 | 0.67–26.05 |
| Smoking | ||||||||
| No | 80 | 54 (67.5) | 19 (23.8) | 73 (91.3) | 7 (8.8) | 1 (Ref) | ||
| Yes | 10 | 5 (50) | 1 (10) | 6 (60) | 4 (40) | 0.004 | 6.95 | 1.58–30.66 |
| ASA stage | ||||||||
| ASA I | 3 | 2 (66.7) | 0 (0) | 2 (66.7) | 1 (33.3) | 1 (Ref) | ||
| ASA II | 61 | 43 (70.5) | 13 (21.3) | 46 (91.8) | 5 (8.2) | 4.6 | 0.35–60.2 | |
| ASA III | 26 | 14 (53.8) | 7 (26.9) | 21 (80.8) | 5 (19.2) | 0.187 | 2.1 | 0.16–28.02 |
| Median/mean value | Maximum | IQR/SD | p-value | |
|---|---|---|---|---|
| Age [years] | ||||
| Total | 59 | 92 | 21 | |
| Sufficient | 60 | 92 | 19 | |
| Insufficient | 55 | 92 | 18 | 0.156 [T test] |
| Body mass index [kg/m2] | ||||
| Total | 27.1 | 41.8 | 5 | |
| Sufficient | 26.5 | 39.4 | 4.5 | |
| Insufficient | 30.7 | 41.8 | 6.6 | 0.008 [T test] |
| Preoperative haemoglobin [g/dl] | ||||
| Total | 12.7 | 17.6 | 2.1 | |
| Sufficient | 12.6 | 17.6 | 2 | |
| Insufficient | 13 | 15.7 | 2.6 | 0.527 [T test] |
| Preoperative leukocytes [1/µl] | ||||
| Total | 7810 | 21,000 | 3250 | |
| Sufficient | 7950 | 21,000 | 3390 | |
| Insufficient | 6830 | 9570 | 1800 | 0.276 [MWU] |
| CRP prior to examination [mg/dl] | ||||
| Total | 6.6 | 17.3 | 4.6 | |
| Sufficient | 6.3 | 17.3 | 4.5 | |
| Insufficient | 9 | 15.1 | 4.6 | 0.054 [MWU] |
X sufficient anastomoses consisting of unsuspicious and suspicious anastomoses, Y analysis related to sufficient and insufficient anastomoses, CI confidence interval, Ref reference, IBD inflammatory bowel disease, RTx radiation therapy, CTx chemotherapy, CRTx concomitant chemoradiotherapy, UICC Union Internationale Contre le Cancer, ASA American Society of Anesthesiologists, MWU Mann–Whitney ranksum test